Platelet-Lymphocyte Ratio as a Predictor of Prognosis in Head and Neck Cancer: A Systematic Review and Meta-Analysis

被引:29
作者
Bardash, Yonatan [1 ,2 ]
Olson, Caitlin [1 ]
Herman, Wendy [2 ]
Khaymovich, Julian [1 ]
Costantino, Peter [1 ,2 ]
Tham, Tristan [1 ]
机构
[1] Northwell Hlth Syst, Lenox Hill Hosp, New York Head & Neck Inst, New York, NY 10021 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY USA
关键词
Platelet-lymphocyte ratio; Inflammatory markers; Prognosis; Head and neck cancer; Meta-analysis; Systematic review; NEUTROPHIL-TO-LYMPHOCYTE; NASOPHARYNGEAL CARCINOMA; HEMATOLOGIC MARKERS; CELL CARCINOMA; INFLAMMATION; THROMBOCYTOSIS;
D O I
10.1159/000502750
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this systematic review and meta-analysis was to investigate the prognostic utility of the platelet-to-lymphocyte ratio (PLR) in head and neck cancer. Medline (via PubMed), EMBASE, Scopus, and the Cochrane Library databases were searched from their inception to May 2017 for relevant literature. A systematic review and meta-analysis were performed to generate the pooled hazard ratios (HR) for overall survival (OS) and disease-specific survival (DSS). The study was conducted in accordance with the Cochrane Handbook and PRISMA guidelines. Risk of bias was assessed using the QUIPS tool. The logarithm of the HR with standard error was used as the primary summary statistic. Heterogeneity was assessed using Cochran's Q and Higgins' I-2. A total of 13 studies were included in the final analysis, combining data from 4,541 patients. The results demonstrated that an elevated PLR was significantly associated with poorer OS [HR 1.85, 95% CI 1.35-2.52, p < 0.00001] and DSS [HR 1.57, 95% CI 1.25-1.97, p < 0.0001]. Significant heterogeneity was detected for the pooled end points. Subgroup analysis demonstrated reduction of heterogeneity by controlling for sample size and cutoff value. 95% prediction intervals showed wide ranges crossing the null threshold.
引用
收藏
页码:665 / 676
页数:12
相关论文
共 52 条
[1]   UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN 657 CONSECUTIVE PATIENTS [J].
ABBRUZZESE, JL ;
ABBRUZZESE, MC ;
HESS, KR ;
RABER, MN ;
LENZI, R ;
FROST, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1272-1280
[2]  
Acharya S, 2017, J INVESTIG CLIN DENT, V8, DOI 10.1111/jicd.12219
[3]   Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe [J].
Aggarwal, Bharat B. ;
Vijayalekshmi, R. V. ;
Sung, Bokyung .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :425-430
[4]  
[Anonymous], 2010, COCHRANE COLLABORATI
[5]  
[Anonymous], 2015, SSRN ELECT J, DOI DOI 10.2139/SSRN.3241355
[6]  
[Anonymous], PLATELET LYMPHOCYTE
[7]  
[Anonymous], 2018, AM J OTOLARYNG, DOI DOI 10.1016/j.amjoto.2018.04.013
[8]  
[Anonymous], HEAD NECK CANC 2017
[9]   Ten Years of Progress in Head and Neck Cancers [J].
Baxi, Shrujal ;
Fury, Matthew ;
Ganly, Ian ;
Rao, Shyam ;
Pfister, David G. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (07) :806-810
[10]   RETRACTED: The preoperative platelet-lymphocyte ratio versus neutrophil-lymphocyte ratio: which is better as a prognostic factor in oral squamous cell carcinoma? (Retracted article. See vol. 14, 2022) [J].
Chen, Shan ;
Guo, Junbing ;
Feng, Chongjin ;
Ke, Zunfu ;
Chen, Leihui ;
Pan, Yunping .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (03) :160-167